Literature DB >> 28259901

Proteomic analysis of oridonin-induced apoptosis in multiple myeloma cells.

Jing Zhao1, Mei Zhang1, Pengcheng He1, Junjie Zhao2, Ying Chen1, Jun Qi3, Yuan Wang1.   

Abstract

Oridonin is a diterpenoid compound isolated from the medicinal herb Rabdosia rubescens, and has shown marked antitumor effects against different types of cancer. However, the definitive systematic molecular mechanism underlying the antitumor activity of oridonin in multiple myeloma remains to be elucidated. In the present study, cell viability and cytotoxicity were examined to determine the appropriate concentration for proteomic investigation. In addition, cell apoptosis was evaluated using flow cytometry and transmission electron microscopy. A proteomic investigation using a two‑dimensional electrophoresis system and mass spectrometry was performed to identify and characterize the global proteome of the apoptosis induced by oridonin. Of the proteins identified, seven were involved in the anticancer effects of oridonin. Regulation of the expression and function of target proteins, stathmin, dihydrofolate reductase and pyruvate dehydrogenase E1β, may be potential, therapeutic strategies to effectively treat multiple myeloma. These findings provide novel information on the molecular mechanisms underlying the anticancer properties of oridonin in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28259901     DOI: 10.3892/mmr.2017.6213

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  4 in total

1.  Oridonin inhibits migration, invasion, adhesion and TGF-β1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3β signaling pathway.

Authors:  Chun-Yu Li; Qi Wang; Shen Shen; Xiao-Lu Wei; Guo-Xia Li
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

Review 2.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

3.  Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers.

Authors:  Xin Leng; Xiaoxv Dong; Wenping Wang; Na Sai; Chunjing Yang; Longtai You; Hongliang Huang; Xingbin Yin; Jian Ni
Journal:  Molecules       Date:  2018-09-28       Impact factor: 4.411

Review 4.  Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity.

Authors:  Xiang Li; Chuan-Tao Zhang; Wei Ma; Xin Xie; Qun Huang
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.